<DOC>
	<DOC>NCT01284608</DOC>
	<brief_summary>This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months</brief_summary>
	<brief_title>Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Prostate cancer patient requiring androgenablation treatment: LHRH analogs, surgical castration, antiandrogen treatment Provision of informed consent prior to conducting any studyrelated procedure Patient involved in a Clinical Trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Observational</keyword>
	<keyword>prospective</keyword>
	<keyword>metabolic changes</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>diabetes</keyword>
	<keyword>prostatic cancer</keyword>
	<keyword>risk fracture</keyword>
</DOC>